^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/05/2018
    Excerpt:
    Femara is an aromatase inhibitor indicated for:...Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

    Excerpt:
    ...- Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy...
    Trial ID:
    SOLE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Dalpiciclib and letrozole combined with trastuzumab / pertuzumab in neoadjuvant treatment of stage II-III HR positive HER2 positive breast cancer: a phase Ib/II study

    Excerpt:
    ...4.Patients with ECOG score of 0-1; 5.Breast cancer patients with HR positive and HER2 positive stage II-III (T2-4a~c, N0-3, M0) who have not received any anti-tumor treatment in the past; 6.Female breast cancer patients with HR positive and HER2 positive confirmed by pathological examination; 7.ER positive and / or PR positive are defined as: the proportion of tumor cells with positive staining in all tumor cells is >= 10% (reviewed and confirmed by the researcher of the test center); HER2 positivity is defined as an immunohistochemical (IHC) score of 3+ or an in situ hybridization (ISH) result of HER2 gene amplification. ...
    Trial ID:
    ChiCTR2200062114
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical study for postmenopausal patients with early breast cancer treated with letrozole for 5 years and withdrawal of 3 months plus transdermal estrogen therapy. Studio clinico per pazienti in postmenopausa operate di tumore mammario candidate ad un trattamento con letrozolo per 5 anni con sospensione di tre mesi e terapia estrogenica somministrata per via transdermica.

    Excerpt:
    ...- Diagnosis of hormone receptor positive tumors. ...
    Trial ID:
    2012-001978-28
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A trial to determine the effect of glucosamine versus placebo on aromatase inhibitor induced arthralgia (joint pain) in postmenopausal women with early breast cancer who are on letrozole

    Excerpt:
    ...Patients must have histologically or cytologically confirmed hormone receptor positive early breast cancer in whom adjuvant treatment with letrozole is planned (initial, switch or extended situations allowed, provided no prior aromatase inhibitor had been used). ...
    Trial ID:
    ACTRN12611000891921
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

    Excerpt:
    ...- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer...
    Trial ID:
    NCT01225172
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

    Excerpt:
    ...Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology....
    Trial ID:
    NCT05744687
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

    Excerpt:
    ...The number of stained cells will be compared in tissue that is hormone receptor-positive tissue to tissue that is hormone receptor negative.`...
    Trial ID:
    NCT00651976
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene

    Excerpt:
    ...Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene in 30 months 6....
    Trial ID:
    LEXTOP
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res Treat
    Title:

    Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea

    Published date:
    08/23/2016
    Excerpt:
    Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.
    DOI:
    10.4143/crt.2016.259